FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Cantabio Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Cantabio Pharmaceuticals, Inc. (CTBO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCTBO
CTBO
Cantabio Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CTBO
Home🔹Stocks🔹Cantabio Pharmaceuticals, Inc.

Cantabio Pharmaceuticals, Inc.

CTBO•OTC

Cantabio Pharmaceuticals, Inc.

CTBO•OTC
Market cap
$22.77K
Sentiment

Your view on CTBO

Mkt Cap
$22.77K
Sentiment
Your view
CTBO
Cantabio Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CTBO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cantabio Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Gergely Toth
Headquarters
2225 East Bayshore Road, Palo Alto, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Gergely Toth
Headquarters
2225 East Bayshore Road, Palo Alto, CA, US
Description

Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News